NCT00874809

Brief Summary

The main purpose of this study is to determine the number of daily basal insulin rate changes that are needed to achieve short-term near normal glucose control in insulin pump patients with type 2 diabetes

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at P25-P50 for not_applicable type-2-diabetes-mellitus

Timeline
Completed

Started Mar 2009

Typical duration for not_applicable type-2-diabetes-mellitus

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2009

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

April 1, 2009

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 3, 2009

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2011

Completed
Last Updated

August 27, 2013

Status Verified

August 1, 2013

Enrollment Period

2.8 years

First QC Date

April 1, 2009

Last Update Submit

August 23, 2013

Conditions

Keywords

insulin pumpDM Type 2CGMSbasal rate

Outcome Measures

Primary Outcomes (1)

  • What are the mean number of changes in the basal infusion rate(change is defined as any alternation in the basal rate >0.1 U/hr) and what are the mean differences and mean duration (hrs) of these changes.

    week six of study

Secondary Outcomes (1)

  • What mathematical formulas describe the relationship between the dosing factors and do they significantly differ from those previously established by King and Armstrong

    week 6 of study

Study Arms (1)

Insulin Treatment

OTHER

There is only one arm for this study using lispro insulin administered by insulin pump.

Device: CGMS with an insulin pump using rapid acting insulin

Interventions

To determine basal changes subject will wear a CGMS with an insulin pump infusing rapid acting insulin

Also known as: Continuous Glucose Monitoring System (CGMS)
Insulin Treatment

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Type 2 diabetes \> 3month duration
  • Age 18
  • Hb A1C \<12%
  • On any hypoglycemic therapy including insulin for 5 patients and 5 patients naive to insulin and failing oral treatment
  • Normal creatine
  • Negative for GAD antibodies
  • SMBG \>4/d and willing/able to comply with study requirements
  • Demonstrated adherence to visits and instructions.

You may not qualify if:

  • Severe hypoglycemic during the last month
  • Severe cardiac, pulmonary or cerebral disease
  • Demonstrated non compliance with clinical recommendations
  • Pregnancy, nursing or women who could potentially become pregnant
  • Presence of physical, psychological or cognitive impairments that would interfere with adherence to an intensive insulin therapy program or compliance with dietary, diary keeping or maintenance of CGM sensor or pump

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Diabetes Care Center

Salinas, California, 93901, United States

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Interventions

Continuous Glucose Monitoring

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

Blood Chemical AnalysisClinical Chemistry TestsClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisDiagnostic Techniques, EndocrineMonitoring, PhysiologicInvestigative Techniques

Study Officials

  • Allen B King, MD

    Diabetes Care Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

April 1, 2009

First Posted

April 3, 2009

Study Start

March 1, 2009

Primary Completion

December 1, 2011

Study Completion

December 1, 2011

Last Updated

August 27, 2013

Record last verified: 2013-08

Locations